Literature DB >> 22234682

Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study.

Junya Kanda1, Masakatsu Hishizawa, Atae Utsunomiya, Shuichi Taniguchi, Tetsuya Eto, Yukiyoshi Moriuchi, Ryuji Tanosaki, Fumio Kawano, Yasushi Miyazaki, Masato Masuda, Koji Nagafuji, Masamichi Hara, Minoko Takanashi, Shunro Kai, Yoshiko Atsuta, Ritsuro Suzuki, Takakazu Kawase, Keitaro Matsuo, Tokiko Nagamura-Inoue, Shunichi Kato, Hisashi Sakamaki, Yasuo Morishima, Jun Okamura, Tatsuo Ichinohe, Takashi Uchiyama.   

Abstract

Allogeneic hematopoietic cell transplantation (HCT) is an effective treatment for adult T-cell leukemia (ATL), raising the question about the role of graft-versus-leukemia effect against ATL. In this study, we retrospectively analyzed the effects of acute and chronic graft-versus-host disease (GVHD) on overall survival, disease-associated mortality, and treatment-related mortality among 294 ATL patients who received allogeneic HCT and survived at least 30 days posttransplant with sustained engraftment. Multivariate analyses treating the occurrence of GVHD as a time-varying covariate demonstrated that the development of grade 1-2 acute GVHD was significantly associated with higher overall survival (hazard ratio [HR] for death, 0.65; P = .018) compared with the absence of acute GVHD. Occurrence of either grade 1-2 or grade 3-4 acute GVHD was associated with lower disease-associated mortality compared with the absence of acute GVHD, whereas grade 3-4 acute GVHD was associated with a higher risk for treatment-related mortality (HR, 3.50; P < .001). The development of extensive chronic GVHD was associated with higher treatment-related mortality (HR, 2.75; P = .006) compared with the absence of chronic GVHD. Collectively, these results indicate that the development of mild-to-moderate acute GVHD confers a lower risk of disease progression and a beneficial influence on survival of allografted patients with ATL.

Entities:  

Mesh:

Year:  2012        PMID: 22234682     DOI: 10.1182/blood-2011-07-368233

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  Administration of an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab, before allogeneic bone marrow transplantation for adult T-cell leukemia/lymphoma.

Authors:  S Haji; J Kiyasu; I Choi; Y Suehiro; K Toyoda; M Tsuda; A Takamatsu; Y Nakashima; H Miyoshi; M Shiratsuchi; S Yamasaki; N Uike; Y Abe
Journal:  Bone Marrow Transplant       Date:  2015-11-02       Impact factor: 5.483

2.  Severe acute graft-versus-host disease increases the incidence of blood stream infection and mortality after allogeneic hematopoietic cell transplantation: Japanese transplant registry study.

Authors:  Yoshitaka Inoue; Keiji Okinaka; Shigeo Fuji; Yoshihiro Inamoto; Naoyuki Uchida; Takashi Toya; Kazuhiro Ikegame; Tetsuya Eto; Yukiyasu Ozawa; Koji Iwato; Yoshinobu Kanda; Yoshiko Atsuta; Masao Ogata; Takahiro Fukuda
Journal:  Bone Marrow Transplant       Date:  2021-04-19       Impact factor: 5.483

Review 3.  Graft-versus-T-cell lymphoma effect: a sustained CR after tapering immunosuppressive drugs in a patient with angioimmunoblastic T-cell lymphoma in relapse after allogeneic transplantation.

Authors:  A C Mamez; L Souchet; D Roos-Weil; M Uzunov; A L Brun; C Algrin; V Leblond; S Nguyen
Journal:  Bone Marrow Transplant       Date:  2014-11-03       Impact factor: 5.483

4.  Characteristic patterns of relapse after allogeneic hematopoietic SCT for adult T-cell leukemia-lymphoma: a comparative study of recurrent lesions after transplantation and chemotherapy by the Nagasaki Transplant Group.

Authors:  H Itonaga; Y Sawayama; J Taguchi; S Honda; H Taniguchi; J Makiyama; E Matsuo; S Sato; K Ando; D Imanishi; Y Imaizumi; S Yoshida; T Hata; Y Moriuchi; T Fukushima; Y Miyazaki
Journal:  Bone Marrow Transplant       Date:  2015-01-26       Impact factor: 5.483

5.  Complete response following toxic epidermal necrolysis in relapsed adult T cell leukemia/lymphoma after haploidentical stem cell transplantation.

Authors:  Satoshi Morishige; Marina Nishi; Hiroshi Saruta; Fumiko Arakawa; Yoshitaka Yamasaki; Shuki Oya; Takayuki Nakamura; Ritsuko Seki; Maki Yamaguchi; Kazutoshi Aoyama; Fumihiko Mouri; Koichi Osaki; Koichi Ohshima; Koji Nagafuji
Journal:  Int J Hematol       Date:  2019-05-31       Impact factor: 2.490

6.  Feasibility of cord blood transplantation in chemosensitive adult T-cell leukemia/lymphoma: a retrospective analysis of the Nagasaki Transplantation Network.

Authors:  Takuya Fukushima; Hidehiro Itonaga; Yukiyoshi Moriuchi; Shinichiro Yoshida; Jun Taguchi; Yoshitaka Imaizumi; Daisuke Imanishi; Hideki Tsushima; Yasushi Sawayama; Emi Matsuo; Tomoko Hata; Yasushi Miyazaki
Journal:  Int J Hematol       Date:  2013-03-13       Impact factor: 2.490

7.  Characterization of patients with aggressive adult T-cell leukemia-lymphoma in Okinawa, Japan: a retrospective analysis of a large cohort.

Authors:  Yukiko Nishi; Takuya Fukushima; Shogo Nomura; Takeaki Tomoyose; Sawako Nakachi; Kazuho Morichika; Iori Tedokon; Keita Tamaki; Natsuki Shimabukuro; Naoya Taira; Takashi Miyagi; Kaori Karimata; Masayo Ohama; Atsushi Yamanoha; Kazumitsu Tamaki; Masaki Hayashi; Hitoshi Arakaki; Jun-Nosuke Uchihara; Kazuiku Ohshiro; Yoshitaka Asakura; Megumi Kuba-Miyara; Kennosuke Karube; Hiroaki Masuzaki
Journal:  Int J Hematol       Date:  2016-06-21       Impact factor: 2.490

8.  Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma with HTLV-1-associated myelopathy.

Authors:  Hikaru Sakamoto; Hidehiro Itonaga; Yasushi Sawayama; Azusa Kojima; Masahiko Chiwata; Machiko Fujioka; Hiroko Kitanosono; Makiko Horai; Teiichiro Miyazaki; Hirokazu Shiraishi; Yoshitaka Imaizumi; Shinichiro Yoshida; Tomoko Hata; Yoshihisa Yamano; Yasushi Miyazaki
Journal:  Int J Hematol       Date:  2021-01-10       Impact factor: 2.490

9.  A Unique T-Cell Receptor Amino Acid Sequence Selected by Human T-Cell Lymphotropic Virus Type 1 Tax301-309-Specific Cytotoxic T Cells in HLA-A24:02-Positive Asymptomatic Carriers and Adult T-Cell Leukemia/Lymphoma Patients.

Authors:  Yuko Ishihara; Yukie Tanaka; Seiichiro Kobayashi; Koji Kawamura; Hideki Nakasone; Ayumi Gomyo; Jin Hayakawa; Masaharu Tamaki; Yu Akahoshi; Naonori Harada; Machiko Kusuda; Kazuaki Kameda; Tomotaka Ugai; Hidenori Wada; Kana Sakamoto; Miki Sato; Kiriko Terasako-Saito; Misato Kikuchi; Shun-Ichi Kimura; Aki Tanihara; Shinichi Kako; Kaoru Uchimaru; Yoshinobu Kanda
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

10.  Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group.

Authors:  Yoshikiyo Ito; Toshihiro Miyamoto; Tomohiko Kamimura; Ken Takase; Hideho Henzan; Yasuo Sugio; Koji Kato; Yuju Ohno; Tetsuya Eto; Takanori Teshima; Koichi Akashi
Journal:  Int J Hematol       Date:  2013-09-17       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.